ImmunityBio (NASDAQ:IBRX) Trading 5.9% Higher – Here’s Why

ImmunityBio, Inc. (NASDAQ:IBRX) rose 5.9% during mid-day trading on Monday . The stock traded as high as $8.22 and last traded at $8.1550. Approximately 4,670,553 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 34,831,793 shares. The stock had previously closed at $7.70.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial launch — ImmunityBio announced ANKTIVA is now commercially available in Saudi Arabia for bladder and lung cancer patients; the company says initial patients have been identified and market entry was achieved quickly after the MENA partnership. ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia
• Positive Sentiment: Analyst reiteration with large upside — D. Boral Capital reaffirmed a “buy” rating and set a $23 price target, implying substantial upside versus the current trading level, which can support investor interest despite legal overhangs. Benzinga
• Positive Sentiment: Founder/market narrative — Coverage notes the stock rally year‑to‑date and the founder highlighting a potential bull case for ANKTIVA (including an immune signal in breast cancer), which fuels speculative upside and investor attention. IBRX stock extends rally: Founder flags fresh bull case for Anktiva
• Neutral Sentiment: Market caution from pundits — Jim Cramer and other commentators have urged waiting for more clarity on ImmunityBio’s data and regulatory status before taking large positions; this creates headline‑driven trading but not a clear directional catalyst. Jim Cramer Suggests Waiting for Clarity on ImmunityBio
• Negative Sentiment: Surge of securities‑fraud solicitations and class actions — Multiple law firms have filed or are soliciting lead‑plaintiff applications for class actions covering purchases between Jan. 19 and Mar. 24, 2026; these notices amplify legal risk and can pressure the stock. Representative filing/notice: IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Levi & Korsinsky
• Negative Sentiment: Allegations tied to FDA warning letter — Some firms and notices cite an FDA warning letter and allege material misstatements about ANKTIVA’s efficacy; one notice quantifies alleged damages (~$1.98 per share) and links the warnings to a prior sharp share decline, which raises potential liability and regulatory risk. ImmunityBio Securities Fraud Class Action – Kahn Swick & Foti

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. BTIG Research started coverage on ImmunityBio in a report on Thursday, March 12th. They issued a “buy” rating and a $13.00 price target on the stock. D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a research report on Tuesday. Finally, HC Wainwright boosted their price objective on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ImmunityBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.40.

ImmunityBio Stock Performance

The business has a 50 day moving average price of $8.06 and a two-hundred day moving average price of $4.82. The company has a market cap of $8.33 billion, a P/E ratio of -21.32 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. As a group, research analysts expect that ImmunityBio, Inc. will post -0.31 EPS for the current year.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 75,000 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the sale, the director owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. This trade represents a 2.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 275,000 shares of company stock valued at $2,934,500. Company insiders own 69.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IBRX. Slow Capital Inc. purchased a new stake in shares of ImmunityBio in the 3rd quarter worth approximately $25,000. Truist Financial Corp purchased a new stake in shares of ImmunityBio in the third quarter worth $27,000. Swiss Life Asset Management Ltd bought a new position in shares of ImmunityBio during the third quarter valued at $27,000. WealthPlan Investment Management LLC purchased a new position in shares of ImmunityBio in the 4th quarter worth about $27,000. Finally, Diversify Advisory Services LLC purchased a new position in shares of ImmunityBio in the 2nd quarter worth about $27,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.